Open AccessIncreased patient co‐payments and changes in PBS‐subsidised prescription medicines dispensed in Western Australia
Author(s) -
Hynd Anna,
Roughead Elizabeth E.,
Preen David B.,
Glover John,
Bulsara Max,
Semmens James
Publication year - 2009
Publication title -
australian and new zealand journal of public health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.946
H-Index - 76
eISSN - 1753-6405
pISSN - 1326-0200
DOI - 10.1111/j.1753-6405.2009.00383.x
Subject(s) - medical prescription , medicine , pharmaceutical benefits scheme , beneficiary , payment , asthma , pharmacoepidemiology , emergency medicine , pediatrics , pharmacology , finance , business
Objective:To determine whether a 24% increase in patient co‐payments in January 2005 and two related co‐payment changes for medicines subsidised under the Australian Pharmaceutical Benefits Scheme (PBS) were associated with changes in dispensings in Western Australia (WA).Method:We analysed aggregate monthly prescription counts and defined daily dose per 1,000 population per day (DDD/1,000/day) for atypical antipsychotics, combination asthma medicines, HmgCoA reductase inhibitors (statins) and proton‐pump inhibitors (PPIs). Trends pre and post the co‐payment increase in January 2005 were compared.Results:In three of the four categories examined, prescription counts were significantly lower following the increase in co‐payment thresholds. Compared with dispensings prior to the co‐payment increase, prescriptions fell by 8% for combination asthma medicines ( p <0.001), 9% for PPIs ( p <0.001) and 5% for statins ( p <0.001). Following the rise in co‐payments, DDD/1,000/day decreased for all four categories. Decreases in dispensings to concessional beneficiaries were between 4% and 5% larger than for general beneficiary patients.Conclusions and Implications:The reduction in the both prescription counts and DDD/1,000/day observed for combination asthma medicines, PPIs and statins, which all remained above co‐payment thresholds, suggests the increase in PBS co‐payments has affected utilisation of these subsidised medicines. The results indicate that increases in patient contributions particularly impact on concessional patients' ability to afford prescription medicines.